Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ticarcillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | RECQL | P46063 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TEK | Q02763 | 1/20 | 0.62 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | RARB | P10826 | 1/20 | 0.60 |
| ▸ | RARG | P13631 | 1/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.60 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticarcillin SCHEMBL10738085 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL10738099 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL34025 | 1.00 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL28757995 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL9929365 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL193733 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935398 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4228859 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935408 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL27742456 | 0.99 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | PTGS1 1076/4885SMN1; SMN2 759/4885KDM4E 1674/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | PTGS1 3135/4885SMN1; SMN2 2904/4885KDM4E 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.